ACADIA Pharmaceuticals Inc. (ACAD) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis.
Analysis Summary
ACADIA Pharmaceuticals Inc. reported revenue of $1.07B in the most recent fiscal year, growing at a 5-year CAGR of 19.4%.
Trailing-twelve-month margins: gross margin 91.1%, operating margin 7.6%, net margin 33.4%.
At the current price of $27.54, ACAD trades at a P/E of 12.10 and an ROE of 32.39%. Market capitalisation stands at $4.7B.
Balance sheet quality for ACAD: current ratio of 3.8, net cash position of $767.5M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Cash flow quality is below average: free cash flow of $105.1M represents 27% conversion of reported net income. High conversion (above 90%) suggests earnings translate cleanly into cash; lower conversion may indicate working capital tightness or accounting timing differences.
Price
| Price | $27.54 |
| Market Cap | $4.7B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 12.10 |
| Price / Book | 3.57 |
| EV / EBITDA | 37.93 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 32.39% |
| Return on Invested Capital | 6.19% |
| Return on Assets | 21.83% |
| Gross Margin | 91.13% |
| Operating Margin | 7.59% |
| Net Margin | 33.42% |
Financial Health
| Debt / Equity | 0.06 |
| Current Ratio | 3.39 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | $4.8B | 12.10 | 3.57 | 32.4% |
| BLTE | Belite Bio, Inc | $6.8B | 8.75 | -10.1% | |
| PRAX | Praxis Precision Medicines, Inc. | $8.7B | 6.71 | -34.1% | |
| IMVT | Immunovant, Inc. | $7.5B | 9.99 | ||
| MIRM | Mirum Pharmaceuticals, Inc. | $5.9B | -410.2% | ||
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.0B | 7.52 | -44.2% | |
| LGND | Ligand Pharmaceuticals Incorporated | $5.7B | 27.49 | 5.71 | |
| DYN | Dyne Therapeutics, Inc. | $3.4B | 4.20 | -64.3% |
Price Performance
| 1 month | -8.75% |
| 3 months | +27.38% |
| Year-to-date | +3.11% |
| 1 year | +13.80% |
| 3 years | +12.78% |
52-Week Range
| 52-week High | $30.96 |
| 52-week Low | $19.69 |
| Avg Volume (90d) | 1.6M |
Related companies: ADMA · BLTE · CRNX · DYN · IMVT · LGND · MIRM
Explore sector: Healthcare · Biotechnology
More sections of ACAD: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks